-
EP2676967
European procedure
Extract from the Register of European Patents
EP About this file: EP2676967
| EP2676967 - Methods of treating inflammatory and autoimmune diseases with natalizumab [Right-click to bookmark this link] | Status | Patent revoked Status updated on 17.02.2023 Database last updated on 22.01.2025 | |
| Former | The patent has been granted Status updated on 12.07.2019 | ||
| Former | Grant of patent is intended Status updated on 01.04.2019 | ||
| Former | Examination is in progress Status updated on 06.12.2016 | Most recent event Tooltip | 17.02.2023 | Revocation of patent | published on 22.03.2023 [2023/12] | Applicant(s) | For all designated states Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US | [2019/33] |
| Former [2018/22] | For all designated states Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 / US | ||
| Former [2015/29] | For all designated states Biogen MA Inc. 250 Binney Street Cambridge, MA 02142 / US | ||
| Former [2013/52] | For all designated states Biogen Idec MA Inc. 14 Cambridge Center Cambridge, MA 02142 / US | Inventor(s) | 01 /
Lieberburg, Ivan 85 Hillcrest Road Berkeley, CA 94705 / US | [2013/52] | Representative(s) | Pohlman, Sandra M. df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München / DE | [2019/33] |
| Former [2013/52] | Duckett, Anthony Joseph, et al Mathys & Squire LLP 120 Holborn London EC1N 2SQ / GB | Application number, filing date | 13175987.0 | 28.02.2007 | [2013/52] | Priority number, date | US20060776931P | 28.02.2006 Original published format: US 776931 P | [2013/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP2676967 | Date: | 25.12.2013 | Language: | EN | [2013/52] | Type: | A3 Search report | No.: | EP2676967 | Date: | 05.03.2014 | Language: | EN | [2014/10] | Type: | B1 Patent specification | No.: | EP2676967 | Date: | 14.08.2019 | Language: | EN | [2019/33] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 31.01.2014 | Classification | IPC: | C07K16/28, A61K39/395, G01N33/53, G01N33/68, A61K39/00, A61K38/21, A61K38/03, A61K45/06, A61K49/00 | [2018/15] | CPC: |
C07K16/2839 (EP,US);
A61K38/03 (EP,US);
A61K38/215 (EP,US);
A61K39/39541 (US);
A61K39/3955 (US);
A61K45/06 (US);
A61K49/0004 (US);
A61P1/04 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
C07K16/2842 (EP,US);
G01N33/6893 (US);
G01N33/6896 (EP,US);
A61K2039/505 (EP,US);
A61K2039/54 (US);
A61K2039/545 (US);
C07K2317/24 (EP,US);
G01N2333/025 (EP,US);
G01N2800/065 (US);
G01N2800/285 (EP,US);
|
| Former IPC [2014/10] | C07K16/28, A61K39/395, G01N33/53, G01N33/68, A61K39/00 | ||
| Former IPC [2013/52] | C07K16/28, A61K39/395, G01N33/53, G01N33/68 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2019/33] |
| Former [2013/52] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | Verfahren zur Behandlung von Entzündungs- und Autoimmunerkrankungen mit Natalizumab | [2013/52] | English: | Methods of treating inflammatory and autoimmune diseases with natalizumab | [2013/52] | French: | Procédés de traitement de maladies inflammatoires et auto-immunes avec du natalizumab | [2013/52] | Examination procedure | 19.08.2014 | Examination requested [2014/39] | 03.03.2016 | Despatch of a communication from the examining division (Time limit: M04) | 14.04.2016 | Observations by third parties | 21.06.2016 | Reply to a communication from the examining division | 01.07.2016 | Observations by third parties | 04.07.2016 | Despatch of a communication from the examining division (Time limit: M04) | 11.11.2016 | Reply to a communication from the examining division | 15.12.2016 | Observations by third parties | 24.02.2017 | Despatch of a communication from the examining division (Time limit: M06) | 06.09.2017 | Reply to a communication from the examining division | 11.07.2018 | Despatch of a communication from the examining division (Time limit: M02) | 30.07.2018 | Reply to a communication from the examining division | 14.03.2019 | Cancellation of oral proceeding that was planned for 14.05.2019 | 02.04.2019 | Communication of intention to grant the patent | 14.05.2019 | Date of oral proceedings (cancelled) | 02.07.2019 | Fee for grant paid | 02.07.2019 | Fee for publishing/printing paid | 02.07.2019 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP07751683.9 / EP1988921 | Divisional application(s) | EP19190770.8 / EP3620469 | EP23199522.6 / EP4276469 | Opposition(s) | Opponent(s) | 01
14.05.2020
ADMISSIBLE Polpharma Biologics S.A. Ul. Trzy Lipy 3 80-172 Gdansk / PL Opponent's representative Wichmann, Hendrik Wuesthoff & Wuesthoff Patentanwälte und Rechtsanwalt PartG mbB Schweigerstraße 2 81541 München / DE | [N/P] |
| Former [2020/25] | |||
| Opponent(s) | 01
14.05.2020
ADMISSIBLE Polpharma Biologics S.A. Ul. Trzy Lipy 3 80-172 Gdansk / PL Opponent's representative Wichmann, Hendrik Wuesthoff & Wuesthoff Patentanwälte PartG mbB Schweigerstraße 2 81541 München / DE | 18.06.2020 | Invitation to proprietor to file observations on the notice of opposition | 28.10.2020 | Reply of patent proprietor to notice(s) of opposition | 21.06.2021 | Date of oral proceedings | 04.10.2021 | Despatch of minutes of oral proceedings | 04.10.2021 | Despatch of communication that the patent will be revoked | 07.12.2022 | Legal effect of revocation of patent [2023/12] | Appeal following opposition | 12.11.2021 | Appeal received No. T1992/21 | 12.11.2021 | Payment of appeal fee | 14.02.2022 | Statement of grounds filed | 07.12.2022 | Result of appeal procedure: appeal of the proprietor was rejected | 13.02.2023 | Despatch of the decision of the Board of Appeal | 07.12.2022 | Date of oral proceedings | Fees paid | Renewal fee | 05.11.2013 | Renewal fee patent year 03 | 05.11.2013 | Renewal fee patent year 04 | 05.11.2013 | Renewal fee patent year 05 | 05.11.2013 | Renewal fee patent year 06 | 05.11.2013 | Renewal fee patent year 07 | 27.02.2014 | Renewal fee patent year 08 | 26.02.2015 | Renewal fee patent year 09 | 26.02.2016 | Renewal fee patent year 10 | 27.02.2017 | Renewal fee patent year 11 | 15.02.2018 | Renewal fee patent year 12 | 26.02.2019 | Renewal fee patent year 13 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | by applicant | US5840299 | US6033665 | US2002197233 | US6551593 | US6602503 |